Challenges and Opportunities in the Use of Biomarkers in Early Phase Trials
In this interview Martin Jenkins, Senior Statistician at AstraZeneca, speaks to Andrea Charles from Pharma IQ, about exploring the potential uses of biomarkers to enhance early clinical development, at which points they should be utilised and how. Jenkins draws attention to the practical challenges that arise in the use of biomarkers and shares his insights on how the role of the statistician has evolved in clinical design and analysis.
To continue reading this story get free access
Please note: That all fields marked with an asterisk (*) are required.